Proteome Sciences (PRM)
PRM Share PerformanceMore
|52 week high||12.5000 22/09/16|
|52 week low||3.2500 15/09/17|
|52 week change||-6.9500 (-66.99%)|
|4 week volume||4,128,050 25/08/17|
Media for (PRM)
Latest News« previous» nextMore
01/09/2017 - 13:01 StockMarketWire
Proteome Sciences confirmed that it has issued and allotted 533,333 ordinary shares as payment for professional services. At...
01/09/2017 - 12:08 RNS
RNS Number: 6020P Proteome Sciences PLC 01 September 2017 1 September2017 Proteome Sciences plc ("Proteome Sciences" or the "Company") Issue of Equity Proteome Sciences (AIM:PRM), announces that it has today issued and allotted 533,333 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") as payment for professional services. Applic...
01/08/2017 - 07:00 RNS
RNS Number: 6491M Proteome Sciences PLC 01 August 2017 1 August 2017 Proteome Sciences plc ("Proteome Sciences" or the "Company") Directorate changes Proteome Sciences (AIM:PRM), is pleased to announce the appointment of Dr Ursula Ney as a Non-executive Director of the Company, with immediate effect, replacing Professor William Dawson who is stand...
25/07/2017 - 07:00 RNS
RNS Number: 9512L Proteome Sciences PLC 25 July 2017 25 July 2017 Proteome Sciences plc ("Proteome Sciences" or the "Company") Interim results for the six months ended 30 June 2017 Proteome Sciences is pleased to announce its unaudited interim results for the six months ended 30 June 2017. Financial highlights: Total revenues increased 21% to 1.36m (2016: 1.12m)...
11/07/2017 - 13:25 StockMarketWire
Proteome Sciences has confirmed that the Company will announce its interim results for the six months ended 30 June on...
11/07/2017 - 12:00 RNS
RNS Number: 7216K Proteome Sciences PLC 11 July 2017 Proteome Sciences plc ("Proteome Sciences" or the "Company") Notice of Results Proteome Sciences will announce its interim results for the six months ended 30 June 2017 on 25 July 2017. For further information: Proteome Sciences plc Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)20 7043 2116 Dr Ian P...
30/06/2017 - 10:31 RNS
RNS Number: 7329J Proteome Sciences PLC 30 June 2017 TR-1:NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii PROTEOME SCIENCES 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights NO An...
30/06/2017 - 07:50 StockMarketWire
Proteome Sciences said Randox Laboratories Ltd presented the first results from a prospective trial using its Rapid Stroke A...
|Dividend yield||0 %|
Equity Research (PRM)
Proteome Sciences plc
Edison Investment Research is terminating coverage on Proteome Sciences (PRM). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now...
Proteome Sciences plc
Proteome Sciences signed its first major biomarker service contract in September. This followed on from the data from the 1,148-patient Alzheimer’s disease (AD) study, which could lead to a blood-...
Latest discussion posts More
“Yes it was 175p (roughy) in late Decemner 2003, Ah the good old days!!! Sentiment has certainy taken a hit (understandably - given the poor performance and lack of revenues!), ...”▼
“BC2000, Sorry, my mistake. TP”▼
“??? What income from Sandoz are you referring to? They produce Biosimilars and Generics and have no motivation for proteomics, at least that is my understanding. Please ...”▼
Codes & Symbols
|Symbols||PRM, LSE:PRM, PRM.L, PRM:LN, LON:PRM, XLON:PRM|